Amylyx Pharmaceuticals, Inc. Revenue Breakdown
No Revenue Breakdown for AMLX on this site yet.
- 2025-12-31: Total revenue $0.00.
- 2024-12-31: Others Not split by product in the filing$87.37M100.00%; Total revenue $87.37M.
- 2023-12-31: Others Not split by product in the filing$380.79M100.00%; Total revenue $380.79M.
- 2022-12-31: Others Not split by product in the filing$22.23M100.00%; Total revenue $22.23M.
Source checked: the stored Revenue Breakdown page for AMLX.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | $0.00 | |
| 2024-12-31 | Not split by product in the filing $87.37M 100.00% | $87.37M |
| 2023-12-31 | Not split by product in the filing $380.79M 100.00% | $380.79M |
| 2022-12-31 | Not split by product in the filing $22.23M 100.00% | $22.23M |
| 2021-12-31 | $285.00K |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product $0.00 | $0.00 |
| 2025-09-30 | Not split by product $0.00 | $0.00 |
| 2025-06-30 | Not split by product $0.00 | $0.00 |
| 2025-03-31 | Not split by product $0.00 | $0.00 |
| 2024-12-31 | Not split by product -$665.00K 100.00% | -$665.00K |
| 2024-09-30 | Not split by product $416.00K 100.00% | $416.00K |
| 2024-06-30 | Not split by product -$1.02M 100.00% | -$1.02M |
| 2024-03-31 | Not split by product $88.64M 100.00% | $88.64M |
| 2023-12-31 | Not split by product $108.45M 100.00% | $108.45M |
| 2023-09-30 | Not split by product $102.69M 100.00% | $102.69M |
| 2023-06-30 | Not split by product $98.22M 100.00% | $98.22M |
| 2023-03-31 | Not split by product $71.43M 100.00% | $71.43M |
| 2022-12-31 | Not split by product $21.89M 100.00% | $21.89M |
| 2022-09-30 | Not split by product $345.00K 100.00% | $345.00K |
| 2021-12-31 | Not split by product $0.00 | $0.00 |
| 2021-09-30 | Not split by product $285.00K 100.00% | $285.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |